Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review

Andrea Casadei Gardini, Daniele Santini, Giuseppe Aprile, Nicola Silvestris, Emanuele Felli, Francesco Giuseppe Foschi, Giorgio Ercolani, Giorgia Marisi, Martina Valgiusti, Alessandro Passardi, Marco Puzzoni, Marianna Silletta, Oronzo Brunetti, Giovanni Gerardo Cardellino, Giovanni Luca Frassineti, Mario Scartozzi

Research output: Contribution to journalReview articlepeer-review


Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rational to combine them. Though the strategy of combining TACE and sorafenib has been increasingly used in patients with unresectable HCC but the current evidence is controversial and its clinical role has not been determined yet. In first-line therapy, patients receiving sorafenib had increased overall survival and progression free survival. Therefore several antiangiogenic agents have entered clinical studies on HCC, many with negative results. This review discusses the current drug development for patients with HCC and role of TACE plus sorafenib.

Original languageEnglish
Pages (from-to)66699-66708
Number of pages10
Issue number39
Publication statusPublished - Jan 1 2017


  • Antiangiogenic
  • Hepatocellular carcinoma
  • Second line
  • Tace
  • Transcatheter arterial chemoembolization

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review'. Together they form a unique fingerprint.

Cite this